Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Oncogenes and Tumor Suppressors

Mitochondrial β-Carotene 9′,10′ Oxygenase Modulates Prostate Cancer Growth via NF-κB Inhibition: A Lycopene-Independent Function

Xiaoming Gong, Raju Marisiddaiah, Susan Zaripheh, Doris Wiener and Lewis P. Rubin
Xiaoming Gong
1Department of Pediatrics, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, Texas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raju Marisiddaiah
2Children's Research Institute, St. Petersburg, Florida.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Zaripheh
3Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doris Wiener
4Moffitt Cancer Center, Tampa, Florida.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lewis P. Rubin
1Department of Pediatrics, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, Texas.
5Department of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, Texas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lewis.rubin@ttuhsc.edu
DOI: 10.1158/1541-7786.MCR-16-0075 Published October 2016
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    BCO2 expression is downregulated in human prostate cancer tissues and cell lines. A, BCO2 protein expression in normal human prostate, BPH, and prostate cancer tissues. The positive control lane (+) contains protein extracted from HEK-293 cells engineered to overexpress the bco2 gene. Western blot analysis was conducted using anti-rabbit antibody against BCO2 protein N-terminal peptide. A representative tissue blot is shown. B, BCO2 expression in normal PrEC and prostate cancer cell lines LNCaP, PC3, C4-2, and DU145. Cell lysates were isolated and 30 μg of protein was subjected to NuPAGE. Equal loading of protein was confirmed by reprobing with a β-actin monoclonal antibody. C, real-time RT-PCR of bco2 gene expression in normal PrEC and the prostate cancer cell lines LNCaP, PC3, C4-2 and DU145. Total RNA was isolated from indicated cell lines, and real-time RT-PCR was performed as described in “Materials and Methods.” Relative fold bco2 expression is presented as 2−ΔΔCt relative to the ΔΔCt of DU145 cells. Data, mean ± SD (n = 3). *, P < 0.05.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Demethylation induces bco2 expression in prostate cancer cells. Normal prostatic epithelial (PrEC) and prostate cancer (LNCaP, PC3, C4-2, DU145) cell lines were treated with 10 μmol/L of the methyltransferase inhibitor 5-aza-2dC or vehicle (DMSO) for 96 hours. Total RNA was isolated and real-time RT-PCR was performed as described in “Materials and Methods.” Relative fold bco2 expression is presented as 2−ΔΔCt relative to controls. Data, mean ± SD (n = 3). *, P < 0.05 compared with controls (DMSO).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Lycopene is differentially accumulated in prostatic epithelial cells and upregulates bco2 gene expression in specific prostate cancer cells. A, normal PrEC and prostate cancer cell lines were treated either with 1 or 3 μmol/L lycopene for 24 hours. Cellular lycopene was extracted and analyzed by HPLC in individual cell lines as described in “Materials and Methods.” Lycopene concentrations in PrEC and prostate cancer cell lines are presented as pmol per million (m) cells. B, prostate cancer cell lines (LNCaP and DU145) were treated with 1 μmol/L lycopene or vehicle (DMSO) for 24 hours. Total RNA was isolated and real-time RT-PCR was performed as described in “Materials and Methods.” Relative fold expression is presented as 2−ΔΔCt compared with DMSO control. Data, mean ± SD (n = 3). *, P < 0.05, lycopene concentration versus control.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Lycopene and a lycopene metabolite inhibit cell growth in specific prostate cancer cells. In these representative experiments, LNCaP cells (8 × 104) were seeded onto 6-well plates, then treated with 1 μmol/L lycopene or apo-10-lycopenal, or vehicle (DMSO) for up to 3 days. Every 24 hours, duplicate samples were trypsinized and counted. Trypan blue exclusion showed no differences in cell death among different conditions (data not shown). Data, mean ± SD (n = 3). *, P < 0.05, lycopene concentration versus control, or apo-10-lycopenal versus control. A, LNCaP cells. B, DU145 cells.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Reexpression of BCO2 inhibits prostate cancer cell proliferation and colony formation. LNCaP (A) or DU145 (B) cells were transiently transfected with an empty vector (pcDNA3), or BCO1 or BCO2 expression constructs for 24 hours, then treated with 1 μmol/L lycopene or DMSO control for 24 hours. Cell number was estimated by the MTT method as described in “Materials and Methods.” Data, mean ± SD (n = 3). *, P < 0.05, BCO2 expression versus vector control. C, Western blot analysis of BCO2 protein expression in pcDNA3, BCO2, or BCO2-mt transfected DU145 cells at 24 hours posttransfection (β-actin detection as loading control). D, colony formation assay for transfected cell lines described in C. Quantification of colonies per well from nine 3-cm dishes for transfected cell lines as above. Data, mean ± SD (n = 3). *, P < 0.05.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Exogenous BCO2 expression inhibits NF-κB transcriptional activity in prostate cancer cells. A, DU145 cells were transiently transfected with a NF-κB luciferase reporter, β-gal (transfection efficiency control), and the indicated expression constructs for 24 hours followed by treatment with either 1 μmol/L lycopene or vehicle for 24 hours; cells were lysed and luciferase assays performed. Data represent mean ± SD (n = 3) normalized to β-gal activity (*, P < 0.05, BCO2, or BCO2-mt expression vs. control). B, C4-2 cells were transiently transfected with the NF-κB-luc reporter gene, β-gal, and the indicated constructs for 24 hours, and then treated with 1 μmol/L lycopene or DMSO for 20 hours. After stimulation with TNFα (10 ng/mL) for 3 hours, cells were assayed for luciferase activity. Data represent mean ± SD (n = 3) normalized to β-gal (*, P < 0.05, BCO2 or BCO2-mt expression vs. control).

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    BCO2 expression does not affect IκBα levels but reduces NF-κB nuclear translocation and DNA binding. A, C4-2 cells were transiently transfected with the indicated constructs for 24 hours and treated with TNFα (10 ng/mL) for 3 hours. Total cellular protein lysates were isolated and IκBα was detected by Western blot analysis using an IκBα-specific antibody and β-actin detection as a loading control. B, DU145 cells were transiently transfected with the indicated constructs for 24 hours. The cellular extracts were separated into nuclear and cytoplasmic fractions and probed for NF-κB p65; β-actin was used as a cytoplasmic marker and loading control; Histone H3 was used as nuclear marker (top). Bottom, quantification was performed using the results from three different transfections and immunoblots (*, P < 0.05, BCO2-wt or BCO2-mt expression vs. pcDNA3, respective subcellular fraction controls). C, DU145 cells were transiently transfected with the indicated constructs for 24 hours and nuclear protein fractions were extracted. OD, optical density. The NF-κB family protein DNA-binding assay is described in “Materials and Methods.”

Additional Files

  • Figures
  • Supplementary Data

    • Supplemental Figure Legends - Figure S1 (Related to Figure 4A): Lycopene and lycopene metabolites inhibit cell growth in C4-2 prostate cancer cells. In these representative experiments, C4-2 cells (8 x 104) were seeded onto 6-well plates, then treated with 1 μM lycopene or apo-10-lycopenal, or vehicle (DMSO) for up to 3 days. Every 24 h, duplicate samples were trypsinized and counted. Data represent mean {plus minus} SD (n=3). Figure S2 (Related to Figure 4B): Lycopene and lycopene metabolites inhibit cell growth in PC3 prostate cancer cells. In these representative experiments, 8 x 104 PC3 cells were seeded onto 6-well plates, then treated with 1 μM lycopene or apo-10-lycopenal, or vehicle (DMSO) for up to 3 days. Every 24 h, duplicate samples were trypsinized and counted. Data represent mean {plus minus} SD (n=3). Figure S3: Sequence alignments of human BCO2, BCO1, RPE65, and bovine RPE65, showing conserved active site residues targeted for mutation (numbered as BCO2): Glu194, His226, His 286, His 387, Glu465, Glu499, His573). Figure S4: A. Active site structure of the human BCO2 enzyme showing the catalytic iron coordination site with four conserved histidine residues and second shell glutamate residues. B. Predicted 3D structure of human BCO2. Seven bladed β-propellers are indicated in yellow (I through VII) and the four α-helices in pink. Figure S5 (Related to Figure 5C,D): A. Representative colony formation assay for transfected C4-2 cells. B. Quantification of colonies per well from two 6-well plates of transfected C4-2 cells indicated in A. Data represent mean {plus minus} SD (n=4); (*, p< 0.05, BCO2 or BCO2-mt vs. control).
PreviousNext
Back to top
Molecular Cancer Research: 14 (10)
October 2016
Volume 14, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mitochondrial β-Carotene 9′,10′ Oxygenase Modulates Prostate Cancer Growth via NF-κB Inhibition: A Lycopene-Independent Function
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Mitochondrial β-Carotene 9′,10′ Oxygenase Modulates Prostate Cancer Growth via NF-κB Inhibition: A Lycopene-Independent Function
Xiaoming Gong, Raju Marisiddaiah, Susan Zaripheh, Doris Wiener and Lewis P. Rubin
Mol Cancer Res October 1 2016 (14) (10) 966-975; DOI: 10.1158/1541-7786.MCR-16-0075

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Mitochondrial β-Carotene 9′,10′ Oxygenase Modulates Prostate Cancer Growth via NF-κB Inhibition: A Lycopene-Independent Function
Xiaoming Gong, Raju Marisiddaiah, Susan Zaripheh, Doris Wiener and Lewis P. Rubin
Mol Cancer Res October 1 2016 (14) (10) 966-975; DOI: 10.1158/1541-7786.MCR-16-0075
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Mechanisms of V561M FGFR1–Driven Drug Resistance
  • DDX3X in DNA Damage and Liver Tumorigenesis
  • Achilles’ Heel of Brain-Metastatic Breast Cancer
Show more Oncogenes and Tumor Suppressors
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement